Helen J. Ross, MD, Professor of Medicine and Director of Research and Clinical Trials at Rush Cancer Center in Chicago, who served as co-principal investigator of LU005 and the Alliance lead investigator. (IMAGE)
Caption
"We are still learning how best to use immunotherapy in limited-stage, small-cell lung cancer. Concurrent immunotherapy with chemoradiotherapy did not improve survival, but we did not find worsened outcomes or unexpected safety signals,” said Helen J. Ross, MD, Professor of Medicine and Director of Research and Clinical Trials at Rush Cancer Center in Chicago, who served as co-principal investigator of LU005 and the Alliance lead investigator.
“Radiation was given either once or twice daily based on investigator’s choice. Although not randomized, our analysis of the radiation fractionation schedule provides indirect evidence that twice-daily radiation therapy may make a difference in outcomes,” Dr. Ross added. “Clinical trials dating to the 1990s showed that twice-daily radiation therapy can improve survival for patients with limited-stage SCLC, but only about 20 percent of patients in the U.S. receive this approach.”
Credit
Rush Cancer Center
Usage Restrictions
none
License
Original content